The Efficacy of L-Arginine for Benign Prostatic Hyperplasia
Abstract
Objective: Recent studies have demonstrated the effectiveness of phosphodiesterase type 5 (PDE5) inhibitor, a known drug for erectile dysfunction, for treating lower urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH). Smooth muscle relaxation mediated by the nitric oxide (NO) pathway has been considered to improve urinary symptoms. Hence, we examined whether the administration of L-arginine as a precursor of NO could improve urinary conditions via the NO pathway. We also studied whether the combination of tamsulosin hydrochloride (tamsulosin), a known therapeutic drug for prostatic hyperplasia, and L-arginine administered as therapeutic agents can provide synergistic effects on BPH. Materials and Methods: The study subjects comprised 21 patients who visited our hospital with the complaint of LUTS diagnosed as BPH, for which the patients received L-arginine at 1,200 mg/day. First, the changes in urinary symptoms associated with the L-arginine administration were evaluated. After a washout period, 0.1-mg/day tamsulosin was administered. Next, a combination of 0.1-mg/day tamsulosin and 1,200-mg/day L-arginine was administered to determine whether the combination therapy has a synergistic effect against LUTS. International Prostate Symptom Score (IPSS), quality of life (QOL) score, maximum urinary flow rate (Qmax), and residual urine volume were measured before and after the administration of each dose of L-arginine. Furthermore, to determine the role of…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.